Design and validation of the first cell-impermeant melatonin receptor agonist

British Journal of Pharmacology

Volumn 174, Issue 14, 2017, Pages 2409-2421

  Gbahou, Florence ^a,b   Cecon, Erika ^a,b   Viault, Guillaume ^c   Gerbier, Romain ^a,b   Jean Alphonse, Frederic ^d   Karamitri, Angeliki ^a,b   Guillaumet, Gérald ^c   Delagrange, Philippe ^e   Friedlander, Robert M ^d   Vilardaga, Jean Pierre ^d   Suzenet, Franck ^c   Jockers, Ralf ^a,b  

^a INSTITUT COCHIN   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c UNIVERSITÉ D'ORLÉANS   (France)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ARRESTIN 2; CYCLIC AMP; ICOA 13; ICOA 9; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; MELATONIN RECEPTOR; MELATONIN RECEPTOR AGONIST; MITOGEN ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; CARBOCYANINE; CYANINE DYE 3; ETHYLAMINE; ICOA-13; INDOLE DERIVATIVE; LIGAND; PYRROLE DERIVATIVE;

ARTICLE; CELL SURFACE; CONTROLLED STUDY; DRUG DESIGN; DRUG DETERMINATION; DRUG PENETRATION; HEK293 CELL LINE; HYDROPHILICITY; INTRACELLULAR SIGNALING; LIPOPHILICITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR AFFINITY; VALIDATION STUDY; AGONISTS; ANIMAL; CELL CULTURE; CELL MEMBRANE PERMEABILITY; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; HUMAN; METABOLISM; MOUSE; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANIMALS; CARBOCYANINES; CELL MEMBRANE PERMEABILITY; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; ETHYLAMINES; HEK293 CELLS; HUMANS; INDOLES; LIGANDS; MICE; MOLECULAR STRUCTURE; PYRROLES; RECEPTORS, MELATONIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 85020428324     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13856     Document Type: Article

References (48)

1. Abadir PM, Foster DB, Crow M, Cooke CA, Rucker JJ, Jain A et al. (2011). Identification and characterization of a functional mitochondrial angiotensin system. Proc Natl Acad Sci U S A 108: 14849–14854.
2. Alexander SP, Davenport AP, Kelly E, Marrion N, Peters JA, Benson HE et al. (2015). The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. Br J Pharmacol 172: 5744–5869.
3. Ayoub MA, Levoye A, Delagrange P, Jockers R (2004). Preferential formation of MT1/MT2 melatonin receptor heterodimers with distinct ligand interaction properties compared with MT2 homodimers. Mol Pharmacol 66: 312–321.
4. Baba K, Benleulmi-Chaachoua A, Journe AS, Kamal M, Guillaume JL, Dussaud S et al. (2013). Heteromeric MT1/MT2 melatonin receptors modulate photoreceptor function. Sci Signal 6: ra89.
5. Baltos JA, Paoletta S, Nguyen AT, Gregory KJ, Tosh DK, Christopoulos A et al. (2016). Structure-activity analysis of biased agonism at the human adenosine A3 receptor. Mol Pharmacol 90: 12–22.
6. Becker-Andre M, Wiesenberg I, Schaeren WN, Andre E, Missbach M, Saurat JH et al. (1994). Pineal gland hormone melatonin binds and activates an orphan of the nuclear receptor superfamily. J Biol Chem 269: 28531–28534.
7. Belous A, Wakata A, Knox CD, Nicoud IB, Pierce J, Anderson CD et al. (2004). Mitochondrial P2Y-like receptors link cytosolic adenosine nucleotides to mitochondrial calcium uptake. J Cell Biochem 92: 1062–1073.
8. Benard G, Massa F, Puente N, Lourenco J, Bellocchio L, Soria-Gomez E et al. (2012). Mitochondrial CB(1) receptors regulate neuronal energy metabolism. Nat Neurosci 15: 558–564.
9. Cecon E, Chen M, Marcola M, Fernandes PA, Jockers R, Markus RP (2015). Amyloid beta peptide directly impairs pineal gland melatonin synthesis and melatonin receptor signaling through the ERK pathway. FASEB J 29: 2566–2582.
10. Chen X, Cui Z, Wei S, Hou J, Xie Z, Peng X et al. (2013). Chronic high glucose induced INS-1beta cell mitochondrial dysfunction: a comparative mitochondrial proteome with SILAC. Proteomics 13: 3030–3039.
11. Curtis MJ, Bond RA, Spina D, Ahluwalia A, Alexander SP, Giembycz MA et al. (2015). Experimental design and analysis and their reporting: new guidance for publication in BJP. Br J Pharmacol 172: 3461–3471.
12. de la Fuente Revenga M, Herrera-Arozamena C, Fernandez-Saez N, Barco G, Garcia-Orue I, Sugden D et al. (2015). New coumarin-based fluorescent melatonin ligands. Design, synthesis and pharmacological characterization. Eur J Med Chem 103: 370–373.
13. DiPilato LM, Cheng X, Zhang J (2004). Fluorescent indicators of cAMP and Epac activation reveal differential dynamics of cAMP signaling within discrete subcellular compartments. Proc Natl Acad Sci U S A 101: 16513–16518.
14. Dubocovich ML, Delagrange P, Krause DN, Sugden D, Cardinali DP, Olcese J (2010). International union of basic and clinical pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors. Pharmacol Rev 62: 343–380.
15. Feinstein TN, Yui N, Webber MJ, Wehbi VL, Stevenson HP, King JD Jr et al. (2013). Noncanonical control of vasopressin receptor type 2 signaling by retromer and arrestin. J Biol Chem 288: 27849–27860.
16. Ferrandon S, Feinstein TN, Castro M, Wang B, Bouley R, Potts JT et al. (2009). Sustained cyclic AMP production by parathyroid hormone receptor endocytosis. Nat Chem Biol 5: 734–742.
17. Guillaume JL, Daulat AM, Maurice P, Levoye A, Migaud M, Brydon L et al. (2008). The PDZ protein mupp1 promotes Gi coupling and signaling of the Mt1 melatonin receptor. J Biol Chem 283: 16762–16771.
18. Irannejad R, Tsvetanova NG, Lobingier BT, von Zastrow M (2015). Effects of endocytosis on receptor-mediated signaling. Curr Opin Cell Biol 35: 137–143.
19. Jetten AM (2009). Retinoid-related orphan receptors (RORs): critical roles in development, immunity, circadian rhythm, and cellular metabolism. Nucl Recept Signal 7: e003.
20. Jockers R, Delagrange P, Dubocovich ML, Markus RP, Renault N, Tosini G et al. (2016). Update on melatonin receptors. IUPHAR Review. Br J Pharmacol 173: 2702–2725.
21. Jockers R, Maurice P, Boutin JA, Delagrange P (2008). Melatonin receptors, heterodimerization, signal transduction and binding sites: what's new? Br J Pharmacol 154: 1182–1195.
22. Kalliolia E, Silajdzic E, Nambron R, Hill NR, Doshi A, Frost C et al. (2014). Plasma melatonin is reduced in Huntington's disease. Mov Disord 29: 1511–1515.
23. Kamal M, Gbahou F, Guillaume JL, Daulat AM, Benleulmi-Chaachoua A, Luka M et al. (2015). Convergence of melatonin and serotonin (5-HT) signaling at MT2/5-HT2C receptor heteromers. J Biol Chem 290: 11537–11546.
24. Kenakin T, Christopoulos A (2013). Signalling bias in new drug discovery: detection, quantification and therapeutic impact. Nat Rev Drug Discov 12: 205–216.
25. Kenakin T, Watson C, Muniz-Medina V, Christopoulos A, Novick S (2012). A simple method for quantifying functional selectivity and agonist bias. ACS Chem Nerosci 3: 193–203.
26. Klein Herenbrink C, Sykes DA, Donthamsetti P, Canals M, Coudrat T, Shonberg J et al. (2016). The role of kinetic context in apparent biased agonism at GPCRs. Nat Commun 7: 10842.
27. Licha K, Riefke B, Ntziachristos V, Becker A, Chance B, Semmler W (2000). Hydrophilic cyanine dyes as contrast agents for near-infrared tumor imaging: synthesis, photophysical properties and spectroscopic in vivo characterization. Photochem Photobiol 72: 392–398.
28. Liu RY, Zhou JN, van Heerikhuize J, Hofman MA, Swaab DF (1999). Decreased melatonin levels in postmortem cerebrospinal fluid in relation to aging, Alzheimer's disease, and apolipoprotein E-epsilon4/4 genotype. J Clin Endocrinol Metab 84: 323–327.
29. Ma L, Jia J, Niu W, Jiang T, Zhai Q, Yang L et al. (2015). Mitochondrial CB1 receptor is involved in ACEA-induced protective effects on neurons and mitochondrial functions. Sci Rep 5: 12440.
30. Mujumdar RB, Ernst LA, Mujumdar SR, Lewis CJ, Waggoner AS (1993). Cyanine dye labeling reagents: sulfoindocyanine succinimidyl esters. Bioconjug Chem 4: 105–111.
31. Pacini N, Borziani F (2016). Oncostatic-cytoprotective effect of melatonin and other bioactive molecules: a common target in mitochondrial respiration. Int J Mol Sci 17.
32. Petit L, Lacroix I, deCoppet P, Strosberg AD, Jockers R (1999). Differential signaling of human Mel1a and Mel1b melatonin receptors through the cyclic guanosine 3 '-5'-monophosphate pathway. Biochem Pharmacol 58: 633–639.
33. Reiter RJ, Tan DX, Kim SJ, Cruz MH (2014). Delivery of pineal melatonin to the brain and SCN: role of canaliculi, cerebrospinal fluid, tanycytes and Virchow-Robin perivascular spaces. Brain Struct Funct 219: 1873–1887.
34. Southan C, Sharman JL, Benson HE, Faccenda E, Pawson AJ, Alexander SP et al. (2016). The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. Nucleic Acids Res 44: D1054–D1068.
35. Tan DX, Manchester LC, Qin L, Reiter RJ (2016). Melatonin: a mitochondrial targeting molecule involving mitochondrial protection and dynamics. Int J Mol Sci 17.
36. Tatikolov AS, Costa SM (2002). Photophysics and photochemistry of hydrophilic cyanine dyes in normal and reverse micelles. Photochem Photobiol Sci 1: 211–218.
37. Thireau J, Marteaux J, Delagrange P, Lefoulon F, Dufourny L, Guillaumet G et al. (2014). Original design of fluorescent ligands by fusing BODIPY and melatonin neurohormone. ACS Med Chem Lett 5: 158–161.
38. Tosini G, Owino S, Guillaume JL, Jockers R (2014). Understanding melatonin receptor pharmacology: latest insights from mouse models, and their relevance to human disease. Bioessays 36: 778–787.
39. Tsvetanova NG, Irannejad R, von Zastrow M (2015). G protein-coupled receptor (GPCR) signaling via heterotrimeric G proteins from endosomes. J Biol Chem 290: 6689–6696.
40. van der Westhuizen ET, Breton B, Christopoulos A, Bouvier M (2014). Quantification of ligand bias for clinically relevant beta2-adrenergic receptor ligands: implications for drug taxonomy. Mol Pharmacol 85: 492–509.
41. Venegas C, Garcia JA, Escames G, Ortiz F, Lopez A, Doerrier C et al. (2012). Extrapineal melatonin: analysis of its subcellular distribution and daily fluctuations. J Pineal Res 52: 217–227.
42. Viault G, Poupart S, Mourlevat-Le Magrex S, Lagaraine C, Devavry S et al. (2016). Design, synthesis and biological evaluation of fluorescent ligands for MT1 and/or MT2 melatonin receptors. RSC Adv 6: 62508–62521.
43. Vilardaga JP, Jean-Alphonse FG, Gardella TJ (2014). Endosomal generation of cAMP in GPCR signaling. Nat Chem Biol 10: 700–706.
44. Wang Q, Zhang H, Xu H, Guo D, Shi H, Li Y et al. (2016). 5-HTR3 and 5-HTR4 located on the mitochondrial membrane and functionally regulated mitochondrial functions. Sci Rep 6: 37336.
45. Wang X, Sirianni A, Pei Z, Cormier K, Smith K, Jiang J et al. (2011). The melatonin MT1 receptor axis modulates mutant Huntingtin-mediated toxicity. J Neurosci 31: 14496–14507.
46. Wu PW, Cheng YM, Hsieh WT, Wang YH, Wei CY, Chou PT (2007). 7-azamelatonin: efficient synthetic routes, excited-state double proton transfer properties and biomedical implications. ChemMedChem 2: 1071–1075.
47. Zhang Y, Cook A, Kim J, Baranov SV, Jiang J, Smith K et al. (2013). Melatonin inhibits the caspase-1/cytochrome c/caspase-3 cell death pathway, inhibits MT1 receptor loss and delays disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 55: 26–35.
48. Zlotos DP, Jockers R, Cecon E, Rivara S, Witt-Enderby PA (2014). MT1 and MT2 melatonin receptors: ligands, models, oligomers, and therapeutic potential. J Med Chem 57: 3161–3185.